Veracyte, Inc. VCYT
Updated: 11 Jun 2026
No signal published yet
We already track Veracyte and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Veracyte, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Veracyte free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In June 2026, Veracyte presented data from the Phase III OPTIMA trial at the ASCO Annual Meeting, showing that its Prosigna genomic test can identify breast cancer patients who can safely avoid chemotherapy. The company also reported Q1 2026 revenue of $139.1 million, representing a 21% increase year-over-year.
What Firelda Watch includes for Veracyte, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Veracyte, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Veracyte free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more